SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is commanding market attention as a critical year-end deadline approaches for its Austin robotaxi service to operate without safety monitors, serving as a pivotal test for its AI and autonomous driving ambitions. The community is intensely divided; bulls foresee a significant rebound driven by anticipated breakthroughs in FSD and robotics, while bears highlight concerns over slowing EV demand, recent battery supply contract cuts, and a valuation heavily reliant on unproven future promises. With upcoming delivery reports also on the horizon, the market's focus remains squarely on these near-term developments to gauge the company's trajectory beyond its traditional automotive segment.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech Inc. ($MTEX) is currently trending with strong community interest, fueled by its notably low public float and increasing buying momentum. Traders are actively anticipating a significant breakout and a potential short squeeze, eyeing key price levels as volume continues to build.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is a major talking point following a proposed business combination with Applied Digital's AI cloud division, ChronoScale, which aims to create an accelerated compute platform. The community is buzzing about this strategic pivot, with strong sentiment around its NVIDIA program acceptance and newly reduced share float amplifying expectations for significant future growth in the artificial intelligence space. Many believe the company is currently undervalued and poised for a substantial rally.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending lower amid widespread bearish sentiment, with investors expressing frustration over recent price declines, year-end tax-loss harvesting, and management's communication approach. Despite this, a committed segment of the community remains bullish, pointing to the acquisition of Homebuyer.com, new CEO Kaz Nejatian's vision for AI integration and 2026 profitability, and anticipating a significant rebound.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to compelling preliminary Phase 3 trial data showing an 80% reduction in breast cancer recurrence, alongside a significant show of insider confidence with the Board extending share lock-ups until September 2026. This news has intensified community discussions around a potential short squeeze, given the stock's extremely low float and high cost to borrow, as investors anticipate substantial upside for this undervalued immunotherapy company.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant discussion following recent positive Phase 3 data for relacorilant in platinum-resistant ovarian cancer, which showcased strong efficacy and a comparable safety profile, driving expectations for an upcoming regulatory filing. Community sentiment is highly optimistic about the drug's multi-billion dollar revenue potential and the possibility of a substantial short squeeze, though some anticipate near-term price consolidation after a rapid appreciation. Investors are also closely monitoring upcoming regulatory decisions for relacorilant in Cushing's syndrome and analyzing promising, yet mixed, survival data from its ALS program.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust is highly trending following recent volatility attributed to increased margin requirements on precious metals, leading to forced liquidations and extensive profit-taking. The community is sharply divided, with bulls viewing the pullback as a buying opportunity driven by persistent industrial demand and upcoming export restrictions, while bears anticipate further correction after its rapid ascent.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem is currently a hot topic after discontinuing its RAMP 203 trial to focus on the promising VS-7375 program, a strategic pivot that followed strong Q3 revenue beats. However, a recent $90 million public offering has sparked considerable frustration and debate among investors, many of whom feel betrayed by the dilution despite the company's stated financial position. This has led to accusations of market manipulation and amplified concerns about short selling within a volatile biotech sector.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx (RARE) is trending due to the unexpected failure of its late-stage brittle-bone disease drug, setrusumab, to meet its primary efficacy endpoint in clinical trials, triggering a significant sell-off. This setback has sparked community discussion about the company's immediate outlook and broader biotech sector risks. However, many investors perceive the sharp decline as an overreaction, citing Ultragenyx's portfolio of approved therapies and other pipeline catalysts as a basis for potential recovery.

FONAR Corp. engages in the design, manufacture, sale, and servicing of magnetic resonance imaging scanners. It operates through Manufacturing and Servicing of Medical Equipment, and Management of Diagnostic Imaging Center segments. The Manufacturing and Servicing of Medical Equipment segment promotes its product, Fonar Upright MRI. The Management of Diagnostic Imaging Center segment offers management, administrative, billing and collection services, office space, equipment, repair, maintenance service and clerical, and non-medical personnel to medical providers through its subsidiary, Health Management Corp. of America. The company was founded by Raymond V. Damadian on July 17, 1978 and is headquartered in Melville, NY.

Fonar Corp.

Fonar (FONR) is trending as the company announced a definitive agreement to be taken private by a group led by its CEO at $19.00 per share. This proposed acquisition price has sparked considerable debate among the community, with many shareholders expressing strong frustration, labeling the deal a "robbery" given the company's debt-free balance sheet, significant cash, and a reported book value substantially exceeding the offer. Investors are actively discussing the fairness of the transaction, especially considering the CEO's controlling stake and the company's profitable operations within the healthcare imaging sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
